Abeona Therapeutics, Inc. Stock News

CLEVELAND, Sept. 02, 2025 (GLOBE NEWSWIRE) -- Abeona Therapeutics Inc. (Nasdaq: ABEO) today announced it has granted equity awards to new non-executive employees who joined the Company. The equity awards were approved in accordance with Nasdaq Listing Rule 5635(c)(4).

CLEVELAND, Aug. 29, 2025 (GLOBE NEWSWIRE) -- Abeona Therapeutics Inc. (Nasdaq: ABEO) today announced that members of its management team will participate in upcoming investor conferences in September 2025:

Abeona Therapeutics Inc. (NASDAQ:ABEO ) Q2 2025 Earnings Conference Call August 14, 2025 8:30 AM ET Company Participants Brian Kevany - Senior VP, CTO & CSO Gregory Gin - Vice President of Investor Relations & Corporate Communications Joseph Walter Vazzano - Chief Financial Officer Madhav Vasanthavada - Senior VP, Chief Commercial Officer & Head of Business Development Vishwas Seshadri - Presid...

The FDA's approval and commercial launch of Abeona Therapeutics Inc.'s Zevaskyn for RDEB, plus $155M PRV sale, provides strong financial runway for company for two years. AIM AAV204 capsid platform and ABO-503 gene therapy offer differentiated potential in rare eye disorders, with key catalysts in 2025-2026. ABEO expansion opportunities exist via licensing deals, notably with Beacon Therapeutic...

- Received FDA approval for ZEVASKYN™ (prademagene zamikeracel), the first and only autologous cell-based gene therapy for the treatment of wounds in adult and pediatric patients with recessive dystrophic epidermolysis bullosa (RDEB) -

CLEVELAND, Aug. 01, 2025 (GLOBE NEWSWIRE) -- Abeona Therapeutics Inc. (Nasdaq: ABEO) today announced it has granted equity awards to new non-executive employees who joined the Company. The equity awards were approved in accordance with Nasdaq Listing Rule 5635(c)(4).

BERWYN, Pa., July 29, 2025 (GLOBE NEWSWIRE) -- AscellaHealth, a global partner delivering customizable solutions to support the specialty pharmaceutical industry, highlights the value of its HUB partnership with Abeona Therapeutics Inc. (Nasdaq: ABEO) in the successful pre-and-post launch commercialization of ZEVASKYN™, an FDA-approved cell-based gene therapy.

- Lucile Packard Children's Hospital Stanford is ready to accept patients for ZEVASKYN treatment - - Abeona Therapeutics ® and Stanford Medicine conducted research collaboration for more than a decade, culminating in U.S. Food and Drug Administration (FDA) approval of ZEVASKYN in April 2025 - - ZEVASKYN is the only FDA-approved therapy to treat RDEB wounds with a single application - CLEVELAND,...